Evidence map›Paper›PMID 40636925›Full record

ArticleJournal of vascular anomalies2025

Updated Classification of Vascular Anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group.

Dov Charles Goldenberg, Miikka Vikkula, Anthony Penington, Francine Blei, Leo Schultze Kool, Michel Wassef, Ilona J Frieden, ISSVA Vascular Anomalies Classification Group

Abstract read
In one paragraph

Article in Journal of vascular anomalies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. RAS Inhibitor RMC-7977 Blocks Vascular Overgrowth of NRASJournal of cellular and molecular medicine · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Constitutive, Mosaic Expression of TIE2 p.L914F During Mouse Development Causes Venous Malformation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dov Charles GoldenbergDivision of Plastic Surgery, University of Sao Paulo School of Medicine and Hospital Israelita Albert Einstein, São Paulo, Brazil.
Miikka VikkulaHuman Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium &WELBIO department, WEL Research Institute, avenue Pasteur, 6, 1300 Wavre, Belgium.
Anthony PeningtonDepartment of Paediatrics, University of Melbourne and the Murdoch Children's Research Institute.
Francine BleiNYU Grossman School of Medicine. Hemangioma and Vascular/Lymphatic Malformations Program. New York, New York.
Leo Schultze KoolDepartment of Medical Imaging, Section Interventional Radiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Michel WassefDepartment of Pathology, Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris; Paris Cité University, Paris, France.
Ilona J FriedenDepartments of Dermatology and Pediatrics, University of California San Francisco School of Medicine, San Francisco, California, USA.
ISSVA Vascular Anomalies Classification Group

Funding

Blood vessel assembly from multipotent hemangioma-derived stem cellsR01HL096384 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Joyce E. Bischoff · 2009 to 2026
$7.7M
NHLBI NIH HHS R01 HL096384
6 · The paper itself

Abstract

Introduction: The International Society for the Study of Vascular Anomalies developed in 1996 a Classification of Vascular Anomalies that became internationally accepted. The main feature was the division of vascular anomalies in 2 categories, vascular tumors and malformations. Major revisions occurred in 2014 and 2018, for updates and inclusion of newly described lesions. Major advances occurred in recent years, with improved understanding of genetic basis of vascular anomalies and its relevance in therapeutics. It created a demand for a new revision of ISSVA Classification, and the process is presented in this study. Methods: A group was created in 2019, joining experts from different specialties and coordinated by ISSVA Scientific Committee, to reevaluate the 2018 Classification on each subtype of vascular anomaly, considering the clinical presentation, histological subtypes, flow velocity and genetic aspects. After several multidisciplinary online discussions and in person meetings at ISSVA Congresses (2022, 2023 and 2024) the proposal for the new classification was presented for ISSVA Members ratification, after an opening window for comments and suggestions. A new tool was created, named Results: A new layout of the classification was designed. The visualization begins with a general "Landing Page" where the basic division into vascular tumors and malformations are specified. For vascular tumors, the subdivision was kept between Benign, Borderline and Malignant tumors. For vascular malformations, the divisions were presented as Fast-flow lesions, Slow-flow lesions, and Developmental Anomalies of Named Vessels. A Full Classification Table page with all updated modifications followed the Landing Page. All changes and new terms are described in detail and summarized in a table. The glossary lists and explains, in alphabetic order, all technical terms, abbreviations, acronyms, eponyms, genes and syndromes related to vascular anomalies. Conclusions: The presented updated ISSVA classification of vascular anomalies reflects our evolving understanding of vascular anomalies which will be continuously updated by a dedicated Committee of ISSVA.

Identifiers

PMID40636925
PMCPMC12237419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.